tradingkey.logo
tradingkey.logo

Eli Lilly to sign $2 billion deal for AI drug development with Hong Kong's Insilico Medicine, FT says

ReutersMar 29, 2026 11:13 AM

- Eli Lilly LLY.N will sign a $2 billion deal with Hong Kong-listed biotech Insilico Medicine 3696.HK, which uses artificial intelligence for drug discovery, the Financial Times reported on Sunday.

Lilly will acquire exclusive rights to sell a GLP-1 drug for diabetes from Insilico Medicine, the FT report said, citing sources familiar with the matter.

Reuters could not immediately verify the report.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI